文献速递淋巴瘤白血病

泽布替尼单药治疗B细胞恶性肿瘤患者的汇总安全性分析

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
PubMed 文献 · Blood Adv · 2022-01-01

该汇总安全性分析纳入6项研究共779例接受泽布替尼单药治疗的B细胞恶性肿瘤患者,中位年龄65岁,中位治疗时长26个月。常见非血液学治疗中出现的不良事件为上呼吸道感染(39%)、皮疹(27%)、瘀伤(25%)等,房颤和大出血发生率分别为3%和4%。分析表明泽布替尼总体耐受性良好,安全性特征与已知BTK抑制剂毒性一致,这些毒性可控且大多可逆。

要点

  • 房颤和大出血发生率分别为3%和4%,房颤、高血压和腹泻发生率低于伊布替尼历史报道。
  • 3级及以上不良事件包括中性粒细胞减少(23%)、血小板减少(8%)和贫血(8%)。
  • 因不良事件停药和减量分别占10%和8%,致命性TEAE占4%。

核心结论

  • 泽布替尼总体耐受性良好,安全性特征与已知BTK抑制剂毒性一致,这些毒性可控且大多可逆。

研究设计与样本

  • 汇总6项研究(N=779)中接受泽布替尼单药治疗的B细胞恶性肿瘤患者数据,评估治疗中出现的不良事件(TEAE)的类型、发生率、严重程度和结局。

主要发现

  • 中位年龄65岁,20%的患者≥75岁;多数患者为华氏巨球蛋白血症(33%)、慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(29%)或套细胞淋巴瘤(19%)。
  • 中位治疗持续时间26个月(范围0.1-65),16%的患者治疗≥3年。
  • 常见非血液学TEAE:上呼吸道感染(39%)、皮疹(27%)、瘀伤(25%)、肌肉骨骼疼痛(24%)、腹泻(23%)、咳嗽(21%)、肺炎(21%)、尿路感染和疲乏(各15%)。
  • 最常见的≥3级TEAE:肺炎(11%)、高血压(5%)、上呼吸道感染、尿路感染、脓毒症、腹泻和肌肉骨骼疼痛(各2%)。
  • 房颤和大出血发生率分别为3%和4%;房颤、高血压和腹泻发生率低于伊布替尼历史报道。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and identify treatment-limiting toxicities. Data were pooled from 6 studies (N = 779). Assessments included type, incidence, severity, and outcome of TEAEs. Median age was 65 years; 20% were ≥75 years old. Most patients had Waldenström macroglobulinemia (33%), chronic lymphocytic leukemia/small lymphocytic lymphoma (29%), or mantle-cell lymphoma (19%). Median treatment duration was 26 months (range, 0.1-65); 16% of patients were treated for ≥3 years. Common nonhematologic TEAEs were upper respiratory tract infection (URI, 39%), rash (27%), bruising (25%), musculoskeletal pain (24%), diarrhea (23%), cough (21%), pneumonia (21%), urinary tract infection (UTI), and fatigue (15% each). Most common grade ≥3 TEAEs were pneumonia (11%), hypertension (5%), URI, UTI, sepsis, diarrhea, and musculoskeletal pain (2% each). Atrial fibrillation and major hemorrhage occurred in 3% and 4% of patients, respectively. Atrial fibrillation, hypertension, and diarrhea occurred at lower rates than those reported historically for ibrutinib. Grade ≥3 adverse events included neutropenia (23%), thrombocytopenia (8%), and anemia (8%). Serious TEAEs included pneumonia (11%), sepsis (2%), and pyrexia (2%).Treatment discontinuations and dose reductions for adverse events occurred in 10% and 8% of patients, respectively. Thirty-nine patients (4%) had fatal TEAEs, including pneumonia (n = 9), sepsis (n = 4), unspecified cause (n = 4), and multiple organ dysfunction syndrome (n = 5). This analysis demonstrates that zanubrutinib is generally well tolerated with a safety profile consistent with known BTK inhibitor toxicities; these were manageable and mostly reversible.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022. PMID: 34724705. doi:10.1182/bloodadvances.2021005621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。